Stock SYNTA PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Synta Pharmaceuticals Corp. Nasdaq

Equities

US87162T2069

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Synta Pharmaceuticals Corp.
Apr. 22 BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
Apr. 22 BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Madrigal Statement on the Passing of Dr. Stephen Harrison
AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
AQ
BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective
MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target
MT
6 Stocks Positioned to Soar as Investors Focus on MASH
AQ
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AQ
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
AQ
Madrigal Pharmaceuticals Says Rezdiffra Available in US
MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
AQ
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing
MT
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AQ
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating
MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
MT
Madrigal Pharmaceuticals Prices $600 Million Public Offering
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. Stock
  5. News Synta Pharmaceuticals Corp.